/PRNewswire/ Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment.
/PRNewswire/ Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment.
Imophoron raises GBP 4 million funding for rapid vaccine development Funds will bring next generation vaccine platform, ADDomer(TM), to clinical stage, initially targeting RSV, COVID, and Chikungunya Bristol, UK, October 7, 2021 - Imophoron, the developer of a novel, next generation rapid-response vac.